Latest Tauriga Sciences Inc. (TAUG) Headlines
Tauriga Sciences Inc. Signs Definitive Agreement to Acquire California's Leading Manufacturer of Topical and Medicinal Cannabis Based Therapeutic Creams
GlobeNewswire - Tue Mar 11, 1:19AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" "TAUG" or "the Company"), a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the signing of a Definitive Agreement ("the definitive agreement") with California's leading manufacturer of topical medicinal cannabis products ("Cannabis Manufacturer") since 2009. The Cannabis Manufacturer has developed both an extensive line of medicinal cannabis products as well as delivery technologies. This unique product line of topical cannabis creams ("cream" or "lotion" or "topical cannabis products") deliver the pain relieving and healing power of cannabis right where its applied and is quickly absorbed through the epidermis, with nearly immediate results that last for hours without psychoactive side effects. Founded in 2009 this Cannabis Manufacturer, with which Tauriga entered into the definitive agreement, is a revenue generating company whose products can be found in more than 100 dispensaries within the State of California. These products were originally developed to assist people with: arthritis, sore/tense muscles, back/neck pain, sports injuries, cramps, spasms, and chronic aches. The long term plan is to aggressively expand its operations to other states and file for multiple patents to protect its unique formulations and delivery technologies.
Tauriga Sciences Inc. Executes $1,000,000 USD Term Sheet With Institutional Investor Following the Company's MOU Signed With California's Leading Manufacturer of Topical and Medicinal Cannabis Products
GlobeNewswire - Mon Mar 03, 6:42AM CST
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license or acquisition agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced the execution of a non-binding term sheet of up to $1,000,000 USD to fund, in part, the Company's previously announced proposed acquisition of California's leading manufacturer of topical and medicinal cannabis products ("the Cannabis Manufacturer"). The final terms between the Company and the institutional investor ("the investor") will be disclosed in a to-be-finalized binding agreement.
Tauriga Sciences Inc. Appoints Dr. Stella M. Sung as Chairman and Chief Executive Officer Effective Immediately
GlobeNewswire - Thu Feb 27, 6:45AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced that the Company's Board of Directors ("Board") has appointed Dr. Stella M. Sung ("Dr. Sung") to the positions of Chairman of the Board ("Chairman") and Chief Executive Officer ("CEO") effective immediately. Previously Dr. Sung has served as the Company's Chief Operating Officer ("COO") since April 15, 2013 and largely focused on scientific based due diligence and on developing and executing an effective business plan for the next phase of the Company's growth. Since the completion of the Pilus Energy LLC ("Pilus") acquisition on January 28, 2014, Dr. Sung has been instrumental in the Company's commercialization efforts and is currently building and expanding the management team for the Company's future. Dr. Sung replaces the outgoing CEO Mr. Seth M. Shaw ("Mr. Shaw"), who will retain the important position of Vice President of Strategic Planning moving forward. In this capacity Mr. Shaw will exclusively focus his efforts on improving the Company's access to capital markets as well as assembling roadshows at which the Company can present to a diversified group of institutional investors.
Tauriga Sciences, Inc. Presentation at WSAF Institutional Investor Conference to Take Place on Monday, March 3, 2014 at 1:35pm EST
GlobeNewswire - Mon Feb 24, 1:20PM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, has today announced that the Company's presentation at the Wall Street Analyst Forum ("WSAF") 24th Annual Institutional Investor Conference ("the Conference") will take place at 1:35pm EST on Monday, March 3, 2014. The presentation will be for a duration of 30 minutes immediately followed by a 10 minute Question and Answer ("Q & A") session. Subsequent to that, the Company will meet privately with a number of institutional investors via a 2:15pm EST break-out session.
Tauriga Sciences Inc. Signs Memorandum of Understanding to Acquire Revenue Generating California Based Manufacturer of Topical and Medicinal Cannabis Products
GlobeNewswire - Wed Feb 19, 6:52AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" "TAUG" or "the Company"), a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the execution of a Memorandum of Understanding ("MOU" or "the agreement") with the manufacturer of California's leading topical medicinal cannabis products ("Cannabis Manufacturer") since 2009. The Cannabis Manufacturer has developed both an extensive line of medicinal cannabis products as well as delivery technologies. This unique product line of topical cannabis lotion ("cream" or "lotion" or "topical cannabis products") delivers the pain relieving and healing power of cannabis right where its applied and is quickly absorbed through the epidermis, with nearly immediate results that last for hours without psychoactive side effects. Founded in 2009 this Cannabis Manufacturer, with which Tauriga entered into the MOU, is a revenue generating company whose products can be found in more than 100 dispensaries within the State of California; revenues are generated from development and licensing of product formulation, as well as laboratory and manufacturing services for the medicinal cannabis industry. These products were originally developed to assist people with: arthritis, sore/tense muscles, back/neck pain, sports injuries, cramps, spasms, and chronic aches. The long term plan is to aggressively expand its operations to other states and file for multiple patents to protect its unique formulations and delivery technologies.
Tauriga Sciences Inc. Appoints San Francisco Based Entrepreneur Mr. Woodrow H. Levin as Member of the Company's Business Advisory Board
GlobeNewswire - Mon Feb 10, 7:02AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the appointment of Mr. Woodrow H. Levin ("Mr. Levin") to the Company's Business Advisory Board. Mr. Levin is a successful San Francisco, California based entrepreneur with proven leadership skills and an excellent rolodex of both institutional investors and venture capital funds. With this appointment of Mr. Levin, Tauriga's business advisory board is now comprised of 6 highly qualified members.
Tauriga Sciences Inc. Executes Five Year Service Agreement With The University of Cincinnati Research Institute
GlobeNewswire - Thu Feb 06, 7:10AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the execution of a multi faceted service agreement ("the agreement") with the University of Cincinnati Research Institute ("UCRI") to facilitate the commercialization of the Company's proprietary bacterial robot ("BactoBot(TM)") technology platform for treatment and remediation of wastewater. Through the signing of this agreement with UCRI, the company gains access to a work class laboratory in preparation for its anticipated two commercial pilot tests. In addition the Company plans to develop new products, such as the PCB remediating Nuclear BactoBot(TM), and the rapid prototyping expertise of the UCRI scientists will be of great value to the Company.
Tauriga Sciences Inc. Announces Upcoming Investor Conference and Presentation Schedule Through June 2014
GlobeNewswire - Fri Jan 31, 7:00AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced that corporate presentations are scheduled at four distinct investment conferences from February 01 through May 31, 2014. These four corporate presentations are booked in: Silicon Valley, New York City, Berlin, and Philadelphia. Most of these events will be webcast or video recorded; webcast details will be distributed as soon as they are available.
Pilus Energy LLC Selected to Present as One of 50 Top Innovators by Venture Summit West 2014 in Silicon Valley on February 12, 2014
GlobeNewswire - Wed Jan 29, 7:00AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced that its Pilus Energy LLC ("Pilus Energy") subsidiary has been selected as one of 50 Top Innovators to present at Venture Summit West 2014. This showcase will take place on February 12, 2014 at the Computer History Museum in Mountain View, California (Silicon Valley). Presenting on behalf of Pilus Energy LLC will be Dr. Stella M. Sung, Chief Operating Officer ("COO") of its parent company Tauriga Sciences, Inc. The extensive list of attending institutional investors and VC firms will provide Pilus Energy with a valuable opportunity to showcase its cutting edge solution to the joined global issues of water and energy.
Tauriga Sciences Inc. Completes Acquisition of Innovative Synthetic Biology Firm Pilus Energy LLC and Positions Itself in Nascent $10 Billion Annual Wastewater-to-Value Market
GlobeNewswire - Tue Jan 28, 8:01AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today completed the acquisition of Cincinnati, Ohio based synthetic biology pioneer Pilus Energy LLC ("Pilus Energy"). Structurally Pilus Energy will operate as a wholly owned subsidiary of Tauriga (pursuant to the terms of the definitive agreement) and will maintain its headquarters location in the State of Ohio. The management of Pilus Energy will report directly to both the Chief Executive Officer ("CEO") and Chief Operating Officer ("COO") of Tauriga with the expectation that at least one board seat of Tauriga will be allocated to a Pilus Energy affiliate. The Board of Directors of Tauriga Sciences unanimously approved both the previously announced definitive merger agreement (11/25/2013) as well as the completion of the acquisition inclusive of amended closing terms.
Tauriga Sciences Inc. Appoints Mr. Jason E. Barkeloo as Member of the Company's Business Advisory Board
GlobeNewswire - Mon Jan 27, 6:59AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the appointment of Mr. Jason E. Barkeloo ("Mr. Barkeloo") to the Company's Business Advisory Board. Mr. Barkeloo currently serves as Chief Executive Officer ("CEO") of Bacterial Robotics LLC ("Bacterial Robotics") and President of each of its two wholly owned subsidiaries: Auricle Solutions ("Auricle Solutions") and Pilus Energy LLC ("Pilus Energy").
Tauriga Sciences Inc. Highlights Pilus Energy's Genetic Rights Management ("GeRM") Keys for the Protection of Its Synthetic Biology Based BactoBots(TM)
GlobeNewswire - Fri Jan 24, 8:10AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today highlighted the Genetic Rights Management ("GeRM") synthetic biology security system developed for Pilus Energy LLC ("Pilus Energy") to protect its proprietary BactoBots(TM) technology platform.
Tauriga Sciences Inc. Repays and Retires Convertible Note Held by Asher Enterprises, Inc. for Principal Amount of $37,500 USD and Issues Important Clarification to Shareholders
GlobeNewswire - Tue Jan 21, 4:59PM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, today announced that it has repaid and retired a convertible note ("the note") held by Asher Enterprises, Inc. ("Asher") for the principal amount of $37,500 USD. On July 17, 2013, Tauriga borrowed $37,500 USD from Asher while the Company was evaluating various business plans and potential opportunities. Including accrued interest and contractual buyout premiums, the note was officially retired for $53,979.45 USD. Therefore, there will be absolutely no share conversions owed to Asher in conjunction with this note and the corresponding debt has been removed from the Company's balance sheet.
Tauriga Sciences Inc. Receives Product Engineering Plan for Polychlorinated Biphenyl Remediating BactoBots(TM) for the Nuclear Industry ("NuclearBot(TM)")
GlobeNewswire - Tue Jan 21, 8:02AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, and its strategic partner Bacterial Robotics LLC ("Bacterial Robotics"), today announced the completion of a confidential whitepaper to engineer and construct a Polychlorinated Biphenyl ("PCB") remediating bacterial robot ("BactoBot(TM)") for the nuclear industry ("NuclearBot(TM)"). Tauriga is planning to add a PCB-degrading, genetically-enhanced organism to its developing line of water remediating technologies and products.
Tauriga Sciences, Inc. Elects to Purchase Key Man Insurance Policies for Both Its Chief Executive Officer and Chief Operating Officer for $6,000,000 USD and $3,000,000 USD Respectively
GlobeNewswire - Fri Jan 17, 7:15AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced that it has elected to purchase two key man insurance policies for both its Chief Executive Officer ("CEO"), Mr. Seth M. Shaw, and its Chief Operating Officer ("COO"), Dr. Stella M. Sung ("Dr. Sung"). These policies will be purchased from Minnesota Life Insurance Company ("Minnesota Life"), for $6,000,000 USD and $3,000,000 USD respectively, providing the company with protection in the event of terminal illness, severe incapacitation, or untimely death afflicting either the CEO or COO. The Company expects that both policies, which carry 5 year initial terms, will be in full effect within the next 10 business days.
Tauriga Sciences Inc. Presents Detailed Illustration of Pilus Energy's GalvaniBot(TM) Powered Electrogenic Bioreactor Waste-to-Value Technology Platform
GlobeNewswire - Thu Jan 16, 6:50AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today presented a graphic illustration of the proprietary Electrogenic Bioreactor ("EBR") developed by Pilus Energy LLC ("Pilus Energy"). This GalvaniBot(TM) powered EBR wastewater-to-value platform promises to provide industrial robust water remediation, electricity generation, biogas and chemical production. GalvaniBot(TM) is housed on the anode of the EBR where the BactoBots(TM) metabolize the organic contaminants as they run through the reactor. These BactoBots(TM) are able to withstand swings in pH and temperature, they resist heavy metals, and are able to not only survive in the presence of other bacteria, but also thrive, acting like microscopic piranhas metabolizing anything organic they come in contact with. In order to prevent escape into the environment or theft of the technology, these BactoBots(TM) must be used in concert with Pilus Energy's GeRM keys.
Tauriga Sciences Inc. Focused on Securing Several Potential Sources of Non-Dilutive Funding
GlobeNewswire - Wed Jan 08, 6:45AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, today announced that it is pursuing several potential sources of non-dilutive funding to assist in completing the acquisition of Pilus Energy LLC ("Pilus Energy"). The Company is focused on several significant opportunities to secure funding from sources that do not require the issuance of equity, such as: grants, low interest loans, and up front exclusive license payments. By obtaining these potential sources of non-dilutive funding, the Company's capital raise requirements could be significantly reduced in addition to any future corresponding dilution.
Tauriga Sciences Inc. Invited to Present at 24th Annual Institutional Investor Conference on March 03, 2014 at The University Club in New York City
GlobeNewswire - Fri Jan 03, 8:00AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced that it has been invited to present at the 24th annual Institutional Investor Conference ("the conference") hosted by The Wall Street Analyst Forum. The conference will take place in New York City at The University Club (located at 1 West 54th Street) on March 03, 2014. Presenting on behalf of Tauriga will be its Chief Executive Officer, Seth M. Shaw, and its Chief Operating Officer, Dr. Stella M. Sung.
Tauriga Sciences Inc. Receives Positive Update From Immunovative Therapies Ltd. and Expected Start Date for Pivotal Phase II/III Breast Cancer Trial
GlobeNewswire - Fri Jan 03, 7:10AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced that it has a received a comprehensive update from Immunovative Therapies Ltd. ("ITL") highlighting some potentially positive developments. On January 02, 2014, the Company was notified that ITL will relaunch clinical trials in Thailand (metastatic cancer) and Israel (liver cancer) later this month. Additionally ITL has definitive plans to launch a pivotal Phase II/III trial (breast cancer) during April-May, 2014.
Tauriga Sciences Inc. Remains Fully Committed to Completing Acquisition of Pilus Energy LLC Despite Recent Share Price Volatility and Sharp Decline
GlobeNewswire - Tue Dec 24, 7:01AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced its strong commitment to the completion of its proposed acquisition with synthetic biology pioneer Pilus Energy LLC ("Pilus Energy"). Since November 25, 2013, when Tauriga announced the definitive agreement to acquire Pilus, the Company has experienced extreme volatility and downward pressure on its stock price. During this period the company has presented to and met with numerous institutional investors and experienced significant levels of interest from potential industry partners and customers throughout the world. The Company has been working diligently to establish a global presence through partnerships and international exclusive licenses, because its proprietary BactoBot technology can potentially address many global water related issues. While the recent share price volatility has been of concern to the company, the company still has 5 months to complete the requisite financing ("financing") and is encouraged by the interest level from the institutional investors. In addition the Company is hopeful that at least a portion of the financing will be non-dilutive, and management is working hard towards that end.
Tauriga Sciences Inc. Signs Definitive Agreement to Acquire California's Leading Manufacturer of Topical and Medicinal Cannabis Based Therapeutic Creams
GlobeNewswire - Tue Mar 11, 1:19AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" "TAUG" or "the Company"), a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the signing of a Definitive Agreement ("the definitive agreement") with California's leading manufacturer of topical medicinal cannabis products ("Cannabis Manufacturer") since 2009. The Cannabis Manufacturer has developed both an extensive line of medicinal cannabis products as well as delivery technologies. This unique product line of topical cannabis creams ("cream" or "lotion" or "topical cannabis products") deliver the pain relieving and healing power of cannabis right where its applied and is quickly absorbed through the epidermis, with nearly immediate results that last for hours without psychoactive side effects. Founded in 2009 this Cannabis Manufacturer, with which Tauriga entered into the definitive agreement, is a revenue generating company whose products can be found in more than 100 dispensaries within the State of California. These products were originally developed to assist people with: arthritis, sore/tense muscles, back/neck pain, sports injuries, cramps, spasms, and chronic aches. The long term plan is to aggressively expand its operations to other states and file for multiple patents to protect its unique formulations and delivery technologies.
Tauriga Sciences Inc. Executes $1,000,000 USD Term Sheet With Institutional Investor Following the Company's MOU Signed With California's Leading Manufacturer of Topical and Medicinal Cannabis Products
GlobeNewswire - Mon Mar 03, 6:42AM CST
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license or acquisition agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced the execution of a non-binding term sheet of up to $1,000,000 USD to fund, in part, the Company's previously announced proposed acquisition of California's leading manufacturer of topical and medicinal cannabis products ("the Cannabis Manufacturer"). The final terms between the Company and the institutional investor ("the investor") will be disclosed in a to-be-finalized binding agreement.
Tauriga Sciences Inc. Appoints Dr. Stella M. Sung as Chairman and Chief Executive Officer Effective Immediately
GlobeNewswire - Thu Feb 27, 6:45AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced that the Company's Board of Directors ("Board") has appointed Dr. Stella M. Sung ("Dr. Sung") to the positions of Chairman of the Board ("Chairman") and Chief Executive Officer ("CEO") effective immediately. Previously Dr. Sung has served as the Company's Chief Operating Officer ("COO") since April 15, 2013 and largely focused on scientific based due diligence and on developing and executing an effective business plan for the next phase of the Company's growth. Since the completion of the Pilus Energy LLC ("Pilus") acquisition on January 28, 2014, Dr. Sung has been instrumental in the Company's commercialization efforts and is currently building and expanding the management team for the Company's future. Dr. Sung replaces the outgoing CEO Mr. Seth M. Shaw ("Mr. Shaw"), who will retain the important position of Vice President of Strategic Planning moving forward. In this capacity Mr. Shaw will exclusively focus his efforts on improving the Company's access to capital markets as well as assembling roadshows at which the Company can present to a diversified group of institutional investors.
Tauriga Sciences, Inc. Presentation at WSAF Institutional Investor Conference to Take Place on Monday, March 3, 2014 at 1:35pm EST
GlobeNewswire - Mon Feb 24, 1:20PM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, has today announced that the Company's presentation at the Wall Street Analyst Forum ("WSAF") 24th Annual Institutional Investor Conference ("the Conference") will take place at 1:35pm EST on Monday, March 3, 2014. The presentation will be for a duration of 30 minutes immediately followed by a 10 minute Question and Answer ("Q & A") session. Subsequent to that, the Company will meet privately with a number of institutional investors via a 2:15pm EST break-out session.
Tauriga Sciences Inc. Signs Memorandum of Understanding to Acquire Revenue Generating California Based Manufacturer of Topical and Medicinal Cannabis Products
GlobeNewswire - Wed Feb 19, 6:52AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" "TAUG" or "the Company"), a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the execution of a Memorandum of Understanding ("MOU" or "the agreement") with the manufacturer of California's leading topical medicinal cannabis products ("Cannabis Manufacturer") since 2009. The Cannabis Manufacturer has developed both an extensive line of medicinal cannabis products as well as delivery technologies. This unique product line of topical cannabis lotion ("cream" or "lotion" or "topical cannabis products") delivers the pain relieving and healing power of cannabis right where its applied and is quickly absorbed through the epidermis, with nearly immediate results that last for hours without psychoactive side effects. Founded in 2009 this Cannabis Manufacturer, with which Tauriga entered into the MOU, is a revenue generating company whose products can be found in more than 100 dispensaries within the State of California; revenues are generated from development and licensing of product formulation, as well as laboratory and manufacturing services for the medicinal cannabis industry. These products were originally developed to assist people with: arthritis, sore/tense muscles, back/neck pain, sports injuries, cramps, spasms, and chronic aches. The long term plan is to aggressively expand its operations to other states and file for multiple patents to protect its unique formulations and delivery technologies.
Tauriga Sciences Inc. Appoints San Francisco Based Entrepreneur Mr. Woodrow H. Levin as Member of the Company's Business Advisory Board
GlobeNewswire - Mon Feb 10, 7:02AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the appointment of Mr. Woodrow H. Levin ("Mr. Levin") to the Company's Business Advisory Board. Mr. Levin is a successful San Francisco, California based entrepreneur with proven leadership skills and an excellent rolodex of both institutional investors and venture capital funds. With this appointment of Mr. Levin, Tauriga's business advisory board is now comprised of 6 highly qualified members.
Tauriga Sciences Inc. Executes Five Year Service Agreement With The University of Cincinnati Research Institute
GlobeNewswire - Thu Feb 06, 7:10AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the execution of a multi faceted service agreement ("the agreement") with the University of Cincinnati Research Institute ("UCRI") to facilitate the commercialization of the Company's proprietary bacterial robot ("BactoBot(TM)") technology platform for treatment and remediation of wastewater. Through the signing of this agreement with UCRI, the company gains access to a work class laboratory in preparation for its anticipated two commercial pilot tests. In addition the Company plans to develop new products, such as the PCB remediating Nuclear BactoBot(TM), and the rapid prototyping expertise of the UCRI scientists will be of great value to the Company.
Tauriga Sciences Inc. Announces Upcoming Investor Conference and Presentation Schedule Through June 2014
GlobeNewswire - Fri Jan 31, 7:00AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced that corporate presentations are scheduled at four distinct investment conferences from February 01 through May 31, 2014. These four corporate presentations are booked in: Silicon Valley, New York City, Berlin, and Philadelphia. Most of these events will be webcast or video recorded; webcast details will be distributed as soon as they are available.
Pilus Energy LLC Selected to Present as One of 50 Top Innovators by Venture Summit West 2014 in Silicon Valley on February 12, 2014
GlobeNewswire - Wed Jan 29, 7:00AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced that its Pilus Energy LLC ("Pilus Energy") subsidiary has been selected as one of 50 Top Innovators to present at Venture Summit West 2014. This showcase will take place on February 12, 2014 at the Computer History Museum in Mountain View, California (Silicon Valley). Presenting on behalf of Pilus Energy LLC will be Dr. Stella M. Sung, Chief Operating Officer ("COO") of its parent company Tauriga Sciences, Inc. The extensive list of attending institutional investors and VC firms will provide Pilus Energy with a valuable opportunity to showcase its cutting edge solution to the joined global issues of water and energy.
Tauriga Sciences Inc. Completes Acquisition of Innovative Synthetic Biology Firm Pilus Energy LLC and Positions Itself in Nascent $10 Billion Annual Wastewater-to-Value Market
GlobeNewswire - Tue Jan 28, 8:01AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today completed the acquisition of Cincinnati, Ohio based synthetic biology pioneer Pilus Energy LLC ("Pilus Energy"). Structurally Pilus Energy will operate as a wholly owned subsidiary of Tauriga (pursuant to the terms of the definitive agreement) and will maintain its headquarters location in the State of Ohio. The management of Pilus Energy will report directly to both the Chief Executive Officer ("CEO") and Chief Operating Officer ("COO") of Tauriga with the expectation that at least one board seat of Tauriga will be allocated to a Pilus Energy affiliate. The Board of Directors of Tauriga Sciences unanimously approved both the previously announced definitive merger agreement (11/25/2013) as well as the completion of the acquisition inclusive of amended closing terms.
Tauriga Sciences Inc. Appoints Mr. Jason E. Barkeloo as Member of the Company's Business Advisory Board
GlobeNewswire - Mon Jan 27, 6:59AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the appointment of Mr. Jason E. Barkeloo ("Mr. Barkeloo") to the Company's Business Advisory Board. Mr. Barkeloo currently serves as Chief Executive Officer ("CEO") of Bacterial Robotics LLC ("Bacterial Robotics") and President of each of its two wholly owned subsidiaries: Auricle Solutions ("Auricle Solutions") and Pilus Energy LLC ("Pilus Energy").
Tauriga Sciences Inc. Highlights Pilus Energy's Genetic Rights Management ("GeRM") Keys for the Protection of Its Synthetic Biology Based BactoBots(TM)
GlobeNewswire - Fri Jan 24, 8:10AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today highlighted the Genetic Rights Management ("GeRM") synthetic biology security system developed for Pilus Energy LLC ("Pilus Energy") to protect its proprietary BactoBots(TM) technology platform.
Tauriga Sciences Inc. Repays and Retires Convertible Note Held by Asher Enterprises, Inc. for Principal Amount of $37,500 USD and Issues Important Clarification to Shareholders
GlobeNewswire - Tue Jan 21, 4:59PM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, today announced that it has repaid and retired a convertible note ("the note") held by Asher Enterprises, Inc. ("Asher") for the principal amount of $37,500 USD. On July 17, 2013, Tauriga borrowed $37,500 USD from Asher while the Company was evaluating various business plans and potential opportunities. Including accrued interest and contractual buyout premiums, the note was officially retired for $53,979.45 USD. Therefore, there will be absolutely no share conversions owed to Asher in conjunction with this note and the corresponding debt has been removed from the Company's balance sheet.
Tauriga Sciences Inc. Receives Product Engineering Plan for Polychlorinated Biphenyl Remediating BactoBots(TM) for the Nuclear Industry ("NuclearBot(TM)")
GlobeNewswire - Tue Jan 21, 8:02AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, and its strategic partner Bacterial Robotics LLC ("Bacterial Robotics"), today announced the completion of a confidential whitepaper to engineer and construct a Polychlorinated Biphenyl ("PCB") remediating bacterial robot ("BactoBot(TM)") for the nuclear industry ("NuclearBot(TM)"). Tauriga is planning to add a PCB-degrading, genetically-enhanced organism to its developing line of water remediating technologies and products.
Tauriga Sciences, Inc. Elects to Purchase Key Man Insurance Policies for Both Its Chief Executive Officer and Chief Operating Officer for $6,000,000 USD and $3,000,000 USD Respectively
GlobeNewswire - Fri Jan 17, 7:15AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced that it has elected to purchase two key man insurance policies for both its Chief Executive Officer ("CEO"), Mr. Seth M. Shaw, and its Chief Operating Officer ("COO"), Dr. Stella M. Sung ("Dr. Sung"). These policies will be purchased from Minnesota Life Insurance Company ("Minnesota Life"), for $6,000,000 USD and $3,000,000 USD respectively, providing the company with protection in the event of terminal illness, severe incapacitation, or untimely death afflicting either the CEO or COO. The Company expects that both policies, which carry 5 year initial terms, will be in full effect within the next 10 business days.
Tauriga Sciences Inc. Presents Detailed Illustration of Pilus Energy's GalvaniBot(TM) Powered Electrogenic Bioreactor Waste-to-Value Technology Platform
GlobeNewswire - Thu Jan 16, 6:50AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today presented a graphic illustration of the proprietary Electrogenic Bioreactor ("EBR") developed by Pilus Energy LLC ("Pilus Energy"). This GalvaniBot(TM) powered EBR wastewater-to-value platform promises to provide industrial robust water remediation, electricity generation, biogas and chemical production. GalvaniBot(TM) is housed on the anode of the EBR where the BactoBots(TM) metabolize the organic contaminants as they run through the reactor. These BactoBots(TM) are able to withstand swings in pH and temperature, they resist heavy metals, and are able to not only survive in the presence of other bacteria, but also thrive, acting like microscopic piranhas metabolizing anything organic they come in contact with. In order to prevent escape into the environment or theft of the technology, these BactoBots(TM) must be used in concert with Pilus Energy's GeRM keys.
Tauriga Sciences Inc. Focused on Securing Several Potential Sources of Non-Dilutive Funding
GlobeNewswire - Wed Jan 08, 6:45AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, today announced that it is pursuing several potential sources of non-dilutive funding to assist in completing the acquisition of Pilus Energy LLC ("Pilus Energy"). The Company is focused on several significant opportunities to secure funding from sources that do not require the issuance of equity, such as: grants, low interest loans, and up front exclusive license payments. By obtaining these potential sources of non-dilutive funding, the Company's capital raise requirements could be significantly reduced in addition to any future corresponding dilution.
Tauriga Sciences Inc. Invited to Present at 24th Annual Institutional Investor Conference on March 03, 2014 at The University Club in New York City
GlobeNewswire - Fri Jan 03, 8:00AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced that it has been invited to present at the 24th annual Institutional Investor Conference ("the conference") hosted by The Wall Street Analyst Forum. The conference will take place in New York City at The University Club (located at 1 West 54th Street) on March 03, 2014. Presenting on behalf of Tauriga will be its Chief Executive Officer, Seth M. Shaw, and its Chief Operating Officer, Dr. Stella M. Sung.
Tauriga Sciences Inc. Receives Positive Update From Immunovative Therapies Ltd. and Expected Start Date for Pivotal Phase II/III Breast Cancer Trial
GlobeNewswire - Fri Jan 03, 7:10AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced that it has a received a comprehensive update from Immunovative Therapies Ltd. ("ITL") highlighting some potentially positive developments. On January 02, 2014, the Company was notified that ITL will relaunch clinical trials in Thailand (metastatic cancer) and Israel (liver cancer) later this month. Additionally ITL has definitive plans to launch a pivotal Phase II/III trial (breast cancer) during April-May, 2014.
Tauriga Sciences Inc. Remains Fully Committed to Completing Acquisition of Pilus Energy LLC Despite Recent Share Price Volatility and Sharp Decline
GlobeNewswire - Tue Dec 24, 7:01AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced its strong commitment to the completion of its proposed acquisition with synthetic biology pioneer Pilus Energy LLC ("Pilus Energy"). Since November 25, 2013, when Tauriga announced the definitive agreement to acquire Pilus, the Company has experienced extreme volatility and downward pressure on its stock price. During this period the company has presented to and met with numerous institutional investors and experienced significant levels of interest from potential industry partners and customers throughout the world. The Company has been working diligently to establish a global presence through partnerships and international exclusive licenses, because its proprietary BactoBot technology can potentially address many global water related issues. While the recent share price volatility has been of concern to the company, the company still has 5 months to complete the requisite financing ("financing") and is encouraged by the interest level from the institutional investors. In addition the Company is hopeful that at least a portion of the financing will be non-dilutive, and management is working hard towards that end.
